Table 2 Laboratory characteristics of our study population.
| Study population at three points in time | 933 (100%) | 355 (38%) | 194/933 (20.8%) | Reference interval |
|---|---|---|---|---|
| TSH (mIU/l) | 2.9 (±7.6) | 1.95 (±3.1) | 2.3 (±5) | 0.27–4.2 |
| fT3 (pg/ml) | 2.3 (±0.6) | 2.9 (±0.5) | 2.9 (±0.85) | 2.0–4.4 |
| fT4 (ng/l) | 13.3 (±3.05) | 13.5 (±2.6) | 13.2 (±2.5) | 9.3–17 |
| Anti-TPO-Ab (kIU/l) | 293.45 (±259.3) | 269.9 (±241) | 251.9 (±244.05) | <34 |
| TRAK (IU/l) | 3.5 (±4) | 4.1 (±17.6) | 5.9 (±39.1) | <1.8 |
| Received LT4 | 747/933 (80%) | 325/355 (91.5%) | 180/195 (92.3%) | |
| LT4 (μg/day) | 96.2 (±41.9) | 94.3 (±45.8) | 94.3 (±38.1) | |
| 25(OH)D (nmol/l) | 43.3 (±23.5) | 48.45 (±26) | 48.4 (±23.5) | ≥ 75 |
| PTH (pmol/l) | 4.9 (±2.6) | 4.8 (±2.2) | 4.8 (±2.3) | 1.6–6.9 |
| Received vitamin D3 | 73/933 (7.8%) | 82/355 (23.1%) | 54/195 (27.7%) | |
| Vitamin D3 (IE/day) | 1998.8 (±3118.6) | 1732.8 (±2367) | 1437.4 (±1149.8) |
TSH: Thyroid-stimulating hormone; fT3: Triiodothyronine; fT4: Free thyroxine; Anti-TPO-Ab: Thyroid perioxidase antibodies; TRAK: Anti-TSH receptor antibodies; LT4: Levothyroxine; 25(OH)D: 25-Hydroxyvitamin D; PTH: Parathyroid hormone.